| scholarly article | Q13442814 |
| P50 | author | Georgie Weston | Q90168281 |
| P2093 | author name string | Christina Founta | |
| Maria Kyrgiou | |||
| Thomas Iftner | |||
| Elisabeth J Adams | |||
| Michael J Harvey | |||
| Caroline Dombrowski | |||
| P2860 | cites work | Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience | Q26745696 |
| A review of the clinical performance of the Aptima HPV assay | Q26776336 | ||
| A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4 | Q30276176 | ||
| Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study | Q30278853 | ||
| APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results | Q30456309 | ||
| Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions | Q34995358 | ||
| Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany | Q35868702 | ||
| Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above | Q35898888 | ||
| Comparing the performance of six human papillomavirus tests in a screening population | Q36663594 | ||
| Cervical cancer screening programmes and policies in 18 European countries | Q36695640 | ||
| Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections | Q36994715 | ||
| The association between knowledge of HPV and feelings of stigma, shame and anxiety. | Q37006074 | ||
| Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study | Q37281729 | ||
| Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older | Q37461977 | ||
| The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening | Q37470374 | ||
| The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy | Q38011639 | ||
| Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer | Q38064070 | ||
| Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials | Q38160099 | ||
| Are 20 human papillomavirus types causing cervical cancer? | Q38240044 | ||
| The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds | Q38928159 | ||
| Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial | Q40405504 | ||
| Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study. | Q40664880 | ||
| A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years | Q40933987 | ||
| Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study | Q43769391 | ||
| Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom | Q43961793 | ||
| The longitudinal clinical performance of the RNA-based AHPV Human Papillomavirus (HPV) Assay in comparison to the DNA-based Hybrid Capture 2 HPV Test in 2 consecutive screening rounds with a 6-year interval in Germany | Q57792215 | ||
| A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion | Q58475803 | ||
| Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening | Q61806246 | ||
| HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system | Q64054260 | ||
| Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial | Q64136355 | ||
| Primary cervical screening with high risk human papillomavirus testing: observational study | Q64232184 | ||
| Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales | Q80015292 | ||
| ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening | Q84853922 | ||
| HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri | Q91039520 | ||
| 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot | Q92603332 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | decision tree | Q831366 |
| P304 | page(s) | e031303 | |
| P577 | publication date | 2020-03-08 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation | |
| P478 | volume | 10 |
Search more.